You are here

Tutorial 4: TELL ME ABOUT ADDITIONAL PHASE II OPPORTUNITIES

Back to Tutorials

Since the Small Business Innovation Research (SBIR) program began over 30 years ago, there have been many accommodations made to address different ways that an eligible small business can meet the objectives of the SBIR program. Most of these variations are associated with Phase II.


As we introduce these variations, it is important to keep in mind that there are significant Agency differences. Therefore, not all of the items discussed will apply in every situation. When in doubt, please contact the SBIR or STTR program manager for the Agency of interest. The newest variations will be introduced first - these were brought about by the SBIR/STTR Reauthorization Act of 2011 and include Direct to Phase II awards, Sequential Phase II awards, Cross-Agency and Cross-program awards, Open Phase II competition, and Award caps.




So, what is a Direct to Phase II award, also referred to as DP2? Direct to Phase II was a pilot program, brought about by the SBIR/STTR Reauthorization Act of 2011, that enabled the National Institutes of Health (NIH), the Department of Defense, and the Department of Education to issue a Phase II award to a small business concern that did not receive a Phase I award for research and development for the same project. Direct to Phase II awards were designed for small business concerns, also known as SBCs that had completed Phase I milestones using non-SBIR funds. The Defense Advanced Research Projects Agency, or DARPA, was the first to implement DP2, followed by NIH and the Air Force. In FY17 when the SBIR/ STTR programs were reauthorized, the pilot programs were not addressed and therefore expired. However, through the National Defense Authorization Act authorized as of August 2018, the pilot programs were reauthorized. It is therefore anticipated that some time in FY19 Direct to Phase II opportunities will be available once again.


Let’s leave this topic and shift to the question of sequential Phase II awards. Recognizing that it takes a long time to mature a technology, the SBIR/STTR Reauthorization Act of 2011 allows a Phase II awardee to receive one additional sequential Phase II award, to continue the work of an initial Phase II award. This additional sequential Phase II award has the same guideline amounts and limits as the initial Phase II award – that is, a guideline amount of $1 million and a limit of $1.5 million. SBCs that are interested in learning more about the application process for sequential Phase IIs should discuss this with their technical monitor or the SBIR/STTR program manager of the Agency with which they are working.



Some variations that you will see are referred to as Phase IIA and Phase IIB awards. Again, please keep in mind that not every Agency offers these awards and that guidelines will vary within Agencies and often between entities within an Agency – so you should discuss these options with the Agency from which you have SBIR or STTR funding. Within the Department of Energy, for example, a Phase II grantee may request additional financial support through a Phase IIA grant. A Phase IIA award allows the grantee to complete the R&D associated with the initial prototype, product, or process development. By contrast, a DOE Phase IIB award provides additional financial support for a new R&D task that extends beyond the scope of the original Phase II grant.


The National Cancer Institute’s (NCI) SBIR program has developed an innovative funding opportunity called the SBIR Phase IIB Bridge Award to support the next stage of development for NIH-funded SBIR Phase II projects in the areas of cancer therapeutics, imaging technologies, interventional devices, diagnostics, and prognostics. The purpose of this award is to address the funding gap known as the “Valley of Death” between the end of the SBIR Phase II award and the subsequent round of financing needed to advance a product or service toward commercialization. To achieve this goal, the Bridge Award funding opportunity is specifically designed to incentivize partnerships between NIH’s SBIR Phase II awardees and third-party investors and/or strategic partners. Both SBIR and STTR Phase II awardees from other Federal Agencies are now welcome to apply.


Two additional capabilities were afforded by the 2011 Reauthorization, referred to as Cross-program and Cross-Agency awards. Cross-program awards enable a Phase I STTR award winner to receive a Phase II SBIR award or the reverse; while the concept of Cross-Agency awards enables any Agency to fund an initiative in Phase II that was initially funded by another Agency in Phase I. This can be particularly helpful when the Agency that funded the Phase I award no longer has the funds to support a Phase II initiative. Be sure to consult with the SBIR program manager responsible for your Phase I award to determine how to take advantage of these opportunities.


Another change brought about by the most recent reauthorization is the Open Phase II competition. While most civilian Agencies have always allowed a Phase I awardee to apply for a Phase II SBIR or STTR award, this was not previously the case with the Department of Defense. In the past, DoD Phase I awardees were invited to submit a Phase II proposal if the Service or Component had an interest in receiving a Phase II proposal from that firm. Now, all DoD Phase I awardees have the opportunity to submit a Phase II proposal to DoD without invitation, but the mechanism for doing so varies by Service and Component.


Finally, across all Agencies a ceiling or cap has been placed on all SBIR/STTR awards. An Agency may provide awards capped at 150% of the base - the cap then is $225,000 for each Phase I award and $1.5 million for each Phase II award. Please note the use of the word “may,” as Agencies have discretion regarding the size of their awards and may offer smaller awards so that the Agency can increase the number of Phase I awards that it makes. In addition, SBA has approved a topics list, which allows budgets to exceed the hard caps as long as the project topics are on the list. HHS has topic waivers for hard caps.


Please keep in mind that although the percentage of funding available through the SBIR and STTR programs has been increasing, the funding for these additional Phase II opportunities comes out of the same pot of money. Each Agency makes a decision about the size and number of awards that it can provide in Phase I, Phase II and as sequential Phase IIs. The Agencies with the smaller budgets are usually not in a position to fund the Phase II opportunities discussed here, but often welcome Cross-Agency awards as a means of bringing in new technologies to their programs that may meet urgent needs. It is the larger Agencies that tend to implement more of these Phase II opportunities. However, keep in mind that competition for additional Phase II opportunities is significant, as the number of these awards is limited. Please be sure to review the guidelines provided by each Agency which offers an SBIR and/ or STTR program and discuss the wisdom of taking advantage of these new opportunities with your technical monitor or the SBIR or STTR program manager.


TUTORIAL 4:
Tell me about additional Phase II Opportunities

Results:


(1) True/False? A sequential Phase II is the same thing as a Second Phase II award?






(2) True/False? It is not possible for an agency to make a Phase II award in excess of $1.5M under any circumstances.






(3) How many sequential Phase II awards may a company receive?








(4) What is the expressed purpose of an NIH SBIR Phase IIB Bridge Award?








(5) A Cross Agency award:






US Flag An Official Website of the United States Government